Repligen's (RGEN) Buy Rating Reaffirmed at HC Wainwright

Repligen (NASDAQ:RGEN - Get Free Report)'s stock had its "buy" rating reiterated by research analysts at HC Wainwright in a research note issued on Monday,Benzinga reports. They currently have a $180.00 price objective on the biotechnology company's stock. HC Wainwright's price target suggests a potential upside of 46.06% from the stock's current price.

Other analysts have also issued reports about the company. JPMorgan Chase & Co. dropped their target price on Repligen from $200.00 to $190.00 and set an "overweight" rating on the stock in a report on Tuesday, April 29th. Canaccord Genuity Group cut their price target on Repligen from $170.00 to $150.00 and set a "hold" rating for the company in a research note on Wednesday, April 16th. TD Cowen initiated coverage on Repligen in a report on Monday, February 10th. They issued a "buy" rating and a $200.00 price objective on the stock. Royal Bank of Canada cut their price objective on Repligen from $202.00 to $189.00 and set an "outperform" rating for the company in a research report on Wednesday, April 30th. Finally, Wolfe Research upgraded Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 target price on the stock in a research report on Tuesday, April 29th. Six equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $173.25.

Repligen Stock Performance

Shares of Repligen stock traded down $4.61 on Monday, reaching $123.24. 580,989 shares of the stock were exchanged, compared to its average volume of 726,090. The business has a 50 day moving average price of $135.03 and a two-hundred day moving average price of $145.32. The firm has a market capitalization of $6.92 billion, a price-to-earnings ratio of -241.65, a PEG ratio of 4.54 and a beta of 1.21. Repligen has a twelve month low of $102.97 and a twelve month high of $182.52. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The biotechnology company reported $0.39 EPS for the quarter, beating the consensus estimate of $0.35 by $0.04. The business had revenue of $169.17 million for the quarter, compared to the consensus estimate of $163.65 million. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The business's revenue for the quarter was up 10.4% on a year-over-year basis. During the same period in the prior year, the firm earned $0.28 EPS. Analysts anticipate that Repligen will post 1.72 earnings per share for the current fiscal year.

Insider Buying and Selling at Repligen

In other news, Director Margaret Pax purchased 250 shares of the stock in a transaction dated Monday, March 17th. The shares were purchased at an average price of $150.69 per share, with a total value of $37,672.50. Following the transaction, the director now owns 1,043 shares in the company, valued at $157,169.67. The trade was a 31.53 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.20% of the stock is owned by company insiders.

Hedge Funds Weigh In On Repligen

A number of institutional investors have recently bought and sold shares of RGEN. Ballentine Partners LLC raised its position in shares of Repligen by 4.0% during the 4th quarter. Ballentine Partners LLC now owns 1,879 shares of the biotechnology company's stock valued at $270,000 after buying an additional 72 shares during the period. CIBC Asset Management Inc raised its position in Repligen by 5.0% in the fourth quarter. CIBC Asset Management Inc now owns 1,706 shares of the biotechnology company's stock valued at $246,000 after purchasing an additional 81 shares during the period. GAMMA Investing LLC lifted its stake in shares of Repligen by 15.2% in the 4th quarter. GAMMA Investing LLC now owns 684 shares of the biotechnology company's stock valued at $98,000 after purchasing an additional 90 shares during the last quarter. Louisiana State Employees Retirement System grew its holdings in shares of Repligen by 0.7% during the 4th quarter. Louisiana State Employees Retirement System now owns 14,500 shares of the biotechnology company's stock worth $2,087,000 after purchasing an additional 100 shares during the period. Finally, Utah Retirement Systems increased its position in shares of Repligen by 1.1% during the 4th quarter. Utah Retirement Systems now owns 9,294 shares of the biotechnology company's stock worth $1,338,000 after purchasing an additional 100 shares during the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.